BIONEUTRAL

BIO PEG Ratio Analysis

1.98x

Higher than 73% of Healthcare sector peers

Updated 1499h ago·SEC filings & market data

Key Takeaway

A PEG ratio of 1.98x means Bio-Rad's stock price is nearly twice its expected earnings growth rate, signaling that investors pay a premium for each unit of future profit growth.

Sector Performance

73th percentile

BIO

1.98x

Sector Median

1.07x

Sector Avg

1.77x

Prior Period

0.03x(Apr 2026)

↓ Declining

📊

Deep Analysis

A PEG ratio of 1.98x means Bio-Rad's stock price is nearly twice its expected earnings growth rate, signaling that investors pay a premium for each unit of future profit growth.

This is well above the healthcare sector median of 1.07x, placing the company in the 73rd percentile among peers, so it is more expensive on a growth-adjusted basis than roughly three-quarters of its sector. The trend data for this metric is N/A, with both year-over-year and quarter-over-quarter changes unavailable, meaning no directional signal can be drawn from recent history. The combination of a high absolute level and an absent trend leaves the valuation risk unresolved: the premium could be justified by stronger fundamentals, but there is no evidence here to confirm it. This metric does not contradict the overall NEUTRAL verdict, as a high PEG ratio alone suggests caution rather than a clear buy or sell signal. Instead, it supports a neutral stance, indicating that growth expectations are already priced in without trend data to suggest they are rising or falling.